EMA Authorised: Defitelio (defibrotide) — Gentium S.r.l.

View source ↗

Summary

Defitelio (defibrotide) has been authorised by the EMA for hepatic veno-occlusive disease, with Gentium S.r.l. as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Veno-occlusive Disease

Drugs mentioned

• Defitelio (defibrotide)

Snippet

Status: Authorised. Therapeutic area: Hepatic Veno-Occlusive Disease. MAH: Gentium S.r.l.. Decision date: 19/12/2023